SAN DIEGO, CA--(Marketwire - November 11, 2008) - BioBlocks, Inc. (BioBlocks), a leading drug discovery chemistry outsourcing partner, and MannKind Corporation (MannKind), a pharmaceutical company focused on treating oncology and diabetes, announced today that they will continue their successful lead optimization collaboration. The two companies have worked together since January 2007, meeting milestones through the synergism of BioBlocks’ expertise in medicinal chemistry and lead optimization with Mannkind’s pioneering insight into novel therapeutic modalities. Key to the success is the two companies’ focus on integrating project management towards a results-based collaboration, rather than relying on fee-for-service outsourcing. Further details and financial terms were not disclosed.
